Filter Results:
(777)
Show Results For
- All HBS Web
(937)
- People (2)
- News (70)
- Research (777)
- Events (1)
- Multimedia (2)
- Faculty Publications (668)
Show Results For
- All HBS Web
(937)
- People (2)
- News (70)
- Research (777)
- Events (1)
- Multimedia (2)
- Faculty Publications (668)
Sort by
- October 2007 (Revised July 2013)
- Case
Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech
By: Robert F. Higgins, Sophie LaMontagne and Brent Kazan
In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates into development. However, several questions related to... View Details
Keywords: Philanthropy; Philanthropy Funding; Innovation; Funding Model; Venture Capital; Partners and Partnerships; Financing and Loans; Investment Funds; Acquisition; Philanthropy and Charitable Giving; Biotechnology Industry; Biotechnology Industry; San Diego
Higgins, Robert F., Sophie LaMontagne, and Brent Kazan. "Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech." Harvard Business School Case 808-005, October 2007. (Revised July 2013.)
- 2019
- Article
Pay-for-Monopoly?: An Assessment of Reverse Payment Deals by Pharmaceutical Companies
By: Sana Rafiq and Max Bazerman
Abstract
Over the past eighteen years, pharmaceutical firms have developed a blueprint to impede competition in order
to maintain their monopoly profits. This scheme, termed pay-for-delay, involves direct or indirect payment of
money from a branded-drug manufacturer... View Details
Rafiq, Sana, and Max Bazerman. "Pay-for-Monopoly? An Assessment of Reverse Payment Deals by Pharmaceutical Companies." Journal of Behavioral Economics for Policy 3, no. 1 (2019): 37–43.
- 2009
- Article
Synthesis by Microbes or Chemists? Pharmaceutical Research and Manufacturing in the Antibiotic Era
By: Arthur A. Daemmrich
This article presents a case study of the rise of Pfizer as a leading pharmaceutical company, with a focus on changing relationships between manufacturing technology and R&D between the mid-1940s and the mid-1960s. Pfizer first moved into pharmaceuticals through... View Details
Keywords: Research and Development; Production; Technology; Transformation; Relationships; Success; Organizations; Programs; Chemicals; Alignment; Pharmaceutical Industry; United States
Daemmrich, Arthur A. "Synthesis by Microbes or Chemists? Pharmaceutical Research and Manufacturing in the Antibiotic Era." History and Technology 23, no. 3 (2009): 237–256.
- February 2001
- Background Note
National Innovation Systems and Comparative Industry Evolution
Discusses U.S. and Japanese innovation systems. Illustrates these with comparative studies of computer and pharmaceutical industries. Probes effects of labor, capital, and customer market institutions on these sectors in the United States and Japan. View Details
Keywords: Industry Growth; Innovation and Invention; Computer Industry; Computer Industry; Japan; United States
Chesbrough, Henry W., and Gillian Morris. "National Innovation Systems and Comparative Industry Evolution." Harvard Business School Background Note 601-049, February 2001.
- March 2024
- Article
Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act
By: Matthew Vogel, Pragya Kakani, Amitabh Chandra and Rena M. Conti
The Inflation Reduction Act (IRA) requires Medicare to negotiate lower prices for some medicines with high Medicare spending. Using historical data from public and proprietary sources to apply the IRA's negotiation criteria retrospectively, we identify all drugs that... View Details
Keywords: Policy; Government Legislation; Health Care and Treatment; Negotiation; Price; Pharmaceutical Industry
Vogel, Matthew, Pragya Kakani, Amitabh Chandra, and Rena M. Conti. "Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act." Nature Biotechnology 42, no. 3 (March 2024): 406–412.
- 2007
- Article
Pharmacovigilance and the Missing Denominator: The Changing Context of Pharmaceutical Risk Mitigation
By: Arthur A. Daemmrich
In the wake of Vioxx, Avandia, and other recent prominent cases of drugs found to cause side effects after marketing, the safety of pharmaceuticals has come to the forefront of American public policy. Press attention, congressional investigations, and legislative... View Details
Keywords: Brands and Branding; Policy; Risk Management; Government Legislation; Risk and Uncertainty; Goals and Objectives; Customers; Pharmaceutical Industry; Pharmaceutical Industry; United States
Daemmrich, Arthur A. "Pharmacovigilance and the Missing Denominator: The Changing Context of Pharmaceutical Risk Mitigation." Pharmacy in History 49, no. 2 (2007): 61–75.
- 2012
- Report
Competing by Saving Lives: How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health
By: Mark R. Kramer, Kyle Peterson, Matthew Rehrig, Mike Stamp and Samuel Kim
Examples of how pharmaceutical and medical companies are addressing unmet health needs in low- and middle- income economies, creating shared value by providing products and services that tackle global health problems. View Details
Keywords: Shared Value; Low- And Middle-income Economies; Health Care and Treatment; Global Range; Pharmaceutical Industry; Pharmaceutical Industry
Kramer, Mark R., Kyle Peterson, Matthew Rehrig, Mike Stamp, and Samuel Kim. "Competing by Saving Lives: How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health." Report, FSG, 2012.
- February 2014
- Case
GSK Sets the Stage for Sustainability in Singapore
By: Vicki L. Sato, Rich Ballenger, Sen Chai, Ross Leimberg and Mariana Mihalusova
- 2014
- Working Paper
The Organizational and Geographic Drivers of Absorptive Capacity: An Empirical Analysis of Pharmaceutical R&D Laboratories
By: Francesca Lazzeri and Gary P. Pisano
Scholars and practitioners alike now recognize that a firm's capacity to assimilate and use know-how from external sources—what Cohen and Levinthal (1990) called "absorptive capacity"—plays a central role in innovation performance. In recent years, a common strategy... View Details
Keywords: Geographic Location; Industry Clusters; Knowledge Acquisition; Pharmaceutical Industry; San Francisco; San Diego; Massachusetts
Lazzeri, Francesca, and Gary P. Pisano. "The Organizational and Geographic Drivers of Absorptive Capacity: An Empirical Analysis of Pharmaceutical R&D Laboratories." Harvard Business School Working Paper, No. 14-098, April 2014.
- November 2016
- Case
QuintilesIMS: Biosimilar Marketing in England
By: John A. Quelch and Emily C. Boudreau
QuintilesIMS was a leading healthcare consulting firm best known for its data and information offerings as well as its market research and management consulting services for life science companies. By 2015, the company was expanding beyond the biopharmaceutical... View Details
Keywords: Health; Pharmaceutical Industry; Biotech; Marketing; Health Care and Treatment; Biotechnology Industry; England
Quelch, John A., and Emily C. Boudreau. "QuintilesIMS: Biosimilar Marketing in England." Harvard Business School Case 517-054, November 2016.
- December 1994 (Revised March 1996)
- Case
Ciba Consumer Pharmaceuticals' Acutrim: Challenges and Opportunities in Today's Diet Industry
By: Nancy F. Koehn and Rebecca Voorheis
Since its introduction in 1983, Acutrim has been a major player in the U.S. appetite suppressant market and in the broader diet industry. This case focuses on the strategic, regulatory, marketing, and financial challenges this product and the rapidly changing diet... View Details
Keywords: Product Marketing; Market Design; Industry Structures; Public Ownership; Problems and Challenges; Opportunities; Food and Beverage Industry; Food and Beverage Industry; United States
Koehn, Nancy F., and Rebecca Voorheis. "Ciba Consumer Pharmaceuticals' Acutrim: Challenges and Opportunities in Today's Diet Industry." Harvard Business School Case 795-043, December 1994. (Revised March 1996.)
- December 2022
- Article
The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies
By: Pragya Kakani, Michael Chernew and Amitabh Chandra
Context: To what extent does pharmaceutical revenue growth depend on new medicines versus increasing prices for existing medicines? Moreover, does using list prices, as is commonly done, instead of prices net of confidential rebates offered by manufacturers, which are... View Details
Kakani, Pragya, Michael Chernew, and Amitabh Chandra. "The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies." Journal of Health Politics, Policy and Law 47, no. 6 (December 2022): 629–648.
- Research Summary
Career Histories and the Biotechnology Industry
Professor Higgins' other major project focuses on the consequences of individuals' career experiences for firms and industries. This second research stream centers on the careers of executives in the biotechnology industry.
Professor Higgins has written... View Details
- Article
Ein Booster für die Pharmabranche [A Booster for the Pharmaceutical Industry]
By: Ariel Dora Stern, Timo Minssen, W. Nicholson Price, II and Christoph Grimpe
mRNA technology has just helped to develop vaccines against COVID-19. Now, like Apple's iOS, it could provide the basis for new innovation platforms. View Details
Keywords: mRNA; COVID-19; Vaccines; Health Care and Treatment; Health Pandemics; Innovation and Invention; Health Industry
Stern, Ariel Dora, Timo Minssen, W. Nicholson Price, II, and Christoph Grimpe. "Ein Booster für die Pharmabranche [A Booster for the Pharmaceutical Industry]." Harvard Business Manager (July 2022).
- November 2016
- Supplement
Alnylam Pharmaceuticals: Building Value from the IP Estate (B)
By: Vicki Sato, Willy Shih and Matt Higgins
The leader of a pioneering biotech company in the siRNA space weighs his options for scaling production capacity in advance of an anticipated commercial launch. Operational complexity and relative merits of in-house manufacturing versus a contractor model are... View Details
Keywords: Pharmaceutical Companies; Pharmaceutical Industry; Biotech; Biotechnology; Operational Complexity; Strategy; Manufacturing; Production; Strategic Planning; Intellectual Property; Biotechnology Industry; United States
Sato, Vicki, Willy Shih, and Matt Higgins. "Alnylam Pharmaceuticals: Building Value from the IP Estate (B)." Harvard Business School Supplement 617-022, November 2016.
- February 2016 (Revised February 2017)
- Case
Alvogen
By: Daniel Isenberg and William Kerr
Alvogen is a young Icelandic generic pharmaceutical company, whose CEO believes that his global strategy will give them an edge in this competitive industry.
Robert Wessman, Alvogen’s CEO, was also previously the CEO of Actavis, another Icelandic generics... View Details
Robert Wessman, Alvogen’s CEO, was also previously the CEO of Actavis, another Icelandic generics... View Details
Keywords: Pharmaceutical Companies; Generic Drugs; Entrepreneurship; Globalization; Risk and Uncertainty; Pharmaceutical Industry; Iceland
Isenberg, Daniel, and William Kerr. "Alvogen." Harvard Business School Case 816-064, February 2016. (Revised February 2017.)
- January 1999
- Background Note
Note on the Drugstore Industry
By: David E. Bell and Ann Leamon
In response to the twin pressures of cross-channel competition and the prevalence of third-party drug plans, drugstores have changed both how they go to market and what they offer once they get there. This note reviews the history of drugstores, presents the current... View Details
- October 2024
- Case
Parexel: Scaling Up and Industry Dynamics
By: Regina E. Herzlinger and Ben Creo
Through the lens of biopharmaceutical contract research organization (CRO) PAREXEL, this case traces the evolution of the firm as it reinvents itself in response to the transformation of the CRO sector from a small, secondary cluster of firms into a major player with... View Details
- July 2019
- Article
The Impact of Price Regulation on the Availability of New Drugs in Germany
By: Ariel Dora Stern, Felicitas Pietrulla, Annika Herr, Aaron S. Kesselheim and Ameet Sarpatwari
The 2011 German Pharmaceutical Market Restructuring Act (“AMNOG”) subjected branded, non-rare disease drugs to price regulation based on an assessment of their clinical benefit. Assessment outcomes range from “major added benefit” to “less benefit than the appropriate... View Details
Keywords: Regulation; Pharmaceuticals; Healthcare; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; Germany
Stern, Ariel Dora, Felicitas Pietrulla, Annika Herr, Aaron S. Kesselheim, and Ameet Sarpatwari. "The Impact of Price Regulation on the Availability of New Drugs in Germany." Health Affairs 38, no. 7 (July 2019): 1182–1187.
- 03 Dec 2001
- Research & Ideas
Healthcare Conference Looks At Ailing Industry
Conference, led by the HBS Health Industry Alumni Association, presented two days of provocative lectures, panel discussions, and case studies surrounding questions like: What's next for healthcare? And how should smart businesses... View Details